Hunan Fangsheng Pharmaceutical (603998) Fundamentals 2026 — P/E 13.4x, Revenue Analysis | SniperIQ
Hunan Fangsheng Pharmaceutical (603998) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥4.1B, trading at ¥9.35 on the SHH. This SniperIQ fundamentals page covers Hunan Fangsheng Pharmaceutical's valuation (P/E 13.4x, P/B 2.4x), profitability (net margin 17.1%), revenue (¥1.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hunan Fangsheng Pharmaceutical's market cap?
Hunan Fangsheng Pharmaceutical (603998) has a market capitalization of approximately ¥4.1B, trading at ¥9.35 on the SHH. Market cap moves with the live share price.
What is Hunan Fangsheng Pharmaceutical's P/E ratio?
Hunan Fangsheng Pharmaceutical's trailing twelve-month P/E ratio is 13.4x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hunan Fangsheng Pharmaceutical?
Hunan Fangsheng Pharmaceutical runs a net profit margin of 17.1%, a gross margin of 73.2%, and an operating margin of 20.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hunan Fangsheng Pharmaceutical generate?
Hunan Fangsheng Pharmaceutical reported revenue of ¥1.7B for fiscal year 2025, with net income of ¥306M and earnings per share (EPS) of 0.7. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hunan Fangsheng Pharmaceutical pay a dividend?
Hunan Fangsheng Pharmaceutical offers a trailing dividend yield of about 4.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hunan Fangsheng Pharmaceutical financially healthy?
Hunan Fangsheng Pharmaceutical carries a debt-to-equity ratio of 0.25x and a current ratio of 0.90x, with a market beta of 0.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hunan Fangsheng Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hunan Fangsheng Pharmaceutical (603998) the key facts are: market cap ¥4.1B, P/E 13.4x, revenue ¥1.7B, 52-week range 8.64-13.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hunan Fangsheng Pharmaceutical's full fundamentals live
Get Hunan Fangsheng Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.